Related Experiment Video
Updated: Jun 8, 2026
07:46
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
Published on: June 18, 2018
Catechol-O-methyltransferase val158met and cognitive function in Parkinson's disease
Jeroen Hoogland1, Rob M A de Bie, Caroline H Williams-Gray
1Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Movement Disorders : Official Journal of the Movement Disorder Society
|September 30, 2010
Summary
The COMT val158met gene variant does not directly impact cognitive function in Parkinson's disease (PD) patients. However, this genetic factor may interact with dopaminergic medication to affect cognitive abilities in individuals with PD.
Area of Science:
- Neuroscience
- Genetics
- Clinical Neurology
Background:
- Cognitive dysfunction is a major non-motor symptom in Parkinson's disease (PD).
- Dopamine homeostasis, crucial for cognition, is regulated by catechol-O-methyltransferase (COMT).
- The COMT val158met polymorphism has been previously linked to executive functions.
Purpose of the Study:
- To investigate the relationship between the COMT val158met polymorphism and cognitive performance in early Parkinson's disease patients.
- To explore potential interactions between COMT genotype and dopaminergic medication on cognition.
Main Methods:
- Neuropsychological testing was conducted on 153 early PD patients.
- COMT val158met genotyping was performed.
- Cognitive data was analyzed in relation to genotype and medication status.
Main Results:
- No direct association was found between COMT val158met genotype and performance on attention or executive function tests.
- A potential interaction between COMT genotype and dopaminergic medication use was observed, influencing cognitive abilities.
Conclusions:
- The COMT val158met genotype alone does not appear to directly determine cognitive function in Parkinson's disease.
- Dopaminergic medication use may modify the effect of the COMT val158met genotype on cognitive performance in PD patients.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...